Immatics (NASDAQ:IMTXW) Short Interest Update

Immatics (NASDAQ:IMTXW) was the target of a significant increase in short interest during the month of July. As of July 31st, there was short interest totalling 1,700 shares, an increase of 6.3% from the July 15th total of 1,600 shares. Based on an average trading volume of 8,000 shares, the short-interest ratio is currently 0.2 days.

Immatics Stock Performance

Shares of IMTXW opened at $2.55 on Tuesday. Immatics has a 1-year low of $1.60 and a 1-year high of $4.14. The firm has a 50-day simple moving average of $3.03 and a two-hundred day simple moving average of $3.00.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.